{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:34:07Z","timestamp":1790447647948,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.critrevonc.2025.104815","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T12:40:10Z","timestamp":1750423210000},"page":"104815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Trimodal treatment vs radical cystectomy for muscle-invasive bladder cancer: The neglected impact of informative censoring. A systematic review and meta-analysis"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6486-2169","authenticated-orcid":false,"given":"Daniele","family":"Robesti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Micheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shesh N.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fallara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine G.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Malavaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104815_bib1","first-page":"11686","article-title":"Propensity score matched survival analysis of octogenarians with muscle-invasive bladder cancer: chemoradiation compared to radical cystectomy","volume":"30","author":"Avudaiappan","year":"2023","journal-title":"Can. J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jval.2013.01.005","article-title":"Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification biasin cancer observational comparative effectiveness research","volume":"16","author":"Bekelman","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2025.104815_bib3","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1002\/cncr.30900","article-title":"Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer","volume":"123","author":"Cahn","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104815_bib4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.564779","article-title":"Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: a meta-analysis","volume":"10","author":"Ding","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib6","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bju.16366","article-title":"Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies","volume":"134","author":"Ditonno","year":"2024","journal-title":"BJU Int."},{"key":"10.1016\/j.critrevonc.2025.104815_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103801","article-title":"Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: a systematic review and meta-analysis","volume":"179","author":"Fallara","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102441","article-title":"Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis","volume":"110","author":"Fallara","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104815_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.euros.2023.03.009","article-title":"Contextualizing olaparib and abiraterone in the current treatment landscape for metastatic castration-resistant prostate cancer","volume":"52","author":"Fallara","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"10.1016\/j.critrevonc.2025.104815_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.04.044","article-title":"Informative censoring of surrogate end-point data in phase 3 oncology trials","volume":"153","author":"Gilboa","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104815_bib11","first-page":"273.e1","article-title":"Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer","volume":"40","author":"Golla","year":"2022","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.critrevonc.2025.104815_bib12","article-title":"Cystectomy vs. bladder preservation after neoadjuvant chemotherapy in muscle-invasive bladder cancer: a tertiary medical center experience","volume":"25","author":"Halabi","year":"2020","journal-title":"Cancer Treat. Res Commun."},{"key":"10.1016\/j.critrevonc.2025.104815_bib13","first-page":"28","article-title":"Can we lower the rates of cystectomy complications by modifying risk factors? A review of the literature","volume":"75","author":"Hladun","year":"2022","journal-title":"Cent. Eur. J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib14","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bju.13900","article-title":"Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy","volume":"120","author":"Huddart","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.critrevonc.2025.104815_bib15","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.21037\/tau-20-1351","article-title":"Relationship of frailty with treatment modality selection in patients with muscle-invasive bladder cancer (FRART-BC study)","volume":"10","author":"Iwamura","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.urology.2019.05.062","article-title":"Chemoradiation Vs radical cystectomy for muscle-invasive bladder cancer: a propensity score-weighted comparative analysis using the national cancer database","volume":"133","author":"Kaushik","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2025.104815_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.urology.2019.05.062","article-title":"Chemoradiation Vs radical cystectomy for muscle-invasive bladder cancer: a propensity score-weighted comparative analysis using the national cancer database","volume":"133","author":"Kaushik","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2025.104815_bib18","doi-asserted-by":"crossref","first-page":"68996","DOI":"10.18632\/oncotarget.16576","article-title":"Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.104815_bib19","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2021.05.009","article-title":"Outcomes for muscle-invasive bladder cancer with radical cystectomy or trimodal therapy in US veterans","volume":"30","author":"Kumar","year":"2021","journal-title":"Eur. Urol. Open Sci."},{"key":"10.1016\/j.critrevonc.2025.104815_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102360","article-title":"Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: a systematic review and meta-analysis","volume":"104","author":"Martini","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104815_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/bju.14872","article-title":"The natural history of untreated muscle-invasive bladder cancer","volume":"125","author":"Martini","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.critrevonc.2025.104815_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2024.11.003","article-title":"Trimodality therapy versus radical cystectomy for muscle-invasive bladder cancer: a systematic review and meta-analysis of matched cohort studies","author":"Matsukawa","year":"2024","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.critrevonc.2025.104815_bib24","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000477912","article-title":"The efficacy of trimodal chemoradiotherapy with cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer","volume":"99","author":"Nagao","year":"2017","journal-title":"Urol. Int"},{"key":"10.1016\/j.critrevonc.2025.104815_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.955894","article-title":"Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation","author":"Nocera","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib26","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/S0140-6736(18)30996-6","article-title":"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial","volume":"391","author":"Parekh","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104815_bib27","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.1080\/03610926.2023.2239397","article-title":"Estimating transition intensity rate on interval-censored data using semi-parametric with EM algorithm approach","volume":"53","author":"Qian","year":"2024","journal-title":"Commun. Stat. Theory Methods"},{"key":"10.1016\/j.critrevonc.2025.104815_bib28","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7306198","article-title":"Comparing long-term survival outcomes for muscle-invasive bladder cancer patients who underwent with radical cystectomy and bladder-sparing trimodality therapy: a multicentre cohort analysis","volume":"2022","author":"Qiu","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib29","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.euf.2024.06.007","article-title":"The impact of second opinion expert pathology review in patient management at the time of transurethral resection of the bladder","volume":"10","author":"Robesti","year":"2024","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.critrevonc.2025.104815_bib30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2017.03.038","article-title":"Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder","volume":"72","author":"Seisen","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib31","doi-asserted-by":"crossref","first-page":"272.e1","DOI":"10.1016\/j.urolonc.2021.12.015","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder","volume":"40","author":"Softness","year":"2022","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","author":"Sterne","year":"2016","journal-title":"BMJ 355"},{"key":"10.1016\/j.critrevonc.2025.104815_bib33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","author":"Vale","year":"2005","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12094-023-03264-9","article-title":"Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival","volume":"26","author":"Tang","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.euo.2018.07.006","article-title":"Systematic review of factors associated with the utilization of radical cystectomy for bladder cancer","volume":"2","author":"Williams","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib36","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamasurg.2018.1680","article-title":"Comparing survival outcomes and costs associated with radical cystectomy and trimodal therapy for older adults with muscle-invasive bladder cancer","volume":"153","author":"Williams","year":"2018","journal-title":"JAMA Surg."},{"key":"10.1016\/j.critrevonc.2025.104815_bib37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.suronc.2016.05.027","article-title":"A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer","volume":"25","author":"Yang","year":"2016","journal-title":"Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/COC.0000000000000471","article-title":"Comparison of outcomes in patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder preservation","volume":"42","author":"Zhong","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104815_bib39","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:10:30Z","timestamp":1758589830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":39,"alternative-id":["S1040842825002033"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104815","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trimodal treatment vs radical cystectomy for muscle-invasive bladder cancer: The neglected impact of informative censoring. A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104815"}}